Methamphetamine
Desoxyn (methamphetamine) is a small molecule pharmaceutical. Methamphetamine was first approved as Desoxyn on 1982-01-01. It is used to treat attention deficit disorder with hyperactivity, narcolepsy, and obesity in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Desoxyn (generic drugs available since 2010-04-21, discontinued: Methampex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methamphetamine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DESOXYN | Key Therapeutics | N-005378 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| desoxyn | New Drug Application | 2022-09-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
| narcolepsy | EFO_0000614 | D009290 | G47.4 |
| obesity | EFO_0001073 | D009765 | E66.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
194 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 6 | 9 | 10 | 5 | 11 | 38 |
| Postoperative pain | D010149 | G89.18 | 2 | 2 | 1 | 15 | 7 | 26 | |
| Pain | D010146 | EFO_0003843 | R52 | 8 | 10 | 4 | 3 | 4 | 25 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 2 | — | 1 | 3 | 10 |
| Chronic pain | D059350 | HP_0012532 | 1 | 1 | 1 | 3 | 3 | 9 | |
| Neonatal abstinence syndrome | D009357 | EFO_0005799 | P96.1 | — | 1 | 2 | 3 | 2 | 8 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | — | 2 | 2 | 1 | 7 |
| Hiv | D006678 | O98.7 | 1 | — | 1 | 3 | 1 | 6 | |
| Heroin dependence | D006556 | EFO_0004240 | 1 | — | 1 | 1 | 3 | 6 | |
| Delirium | D003693 | R41.0 | — | — | — | 1 | 2 | 3 |
Show 21 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 2 | 4 | 3 | — | 3 | 11 | |
| Cocaine-related disorders | D019970 | F14 | 4 | 3 | 1 | — | — | 7 | |
| Cancer pain | D000072716 | G89.3 | — | — | 2 | — | 2 | 4 | |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | 2 | 3 |
| Hepatitis c | D006526 | B19.2 | 2 | — | 1 | — | — | 3 | |
| Scoliosis | D012600 | EFO_0004273 | M41 | 1 | — | 2 | — | — | 3 |
| Opiate substitution treatment | D058850 | — | — | 2 | — | — | 2 | ||
| Acute pain | D059787 | R52 | 1 | — | 1 | — | — | 2 | |
| Palliative care | D010166 | — | 1 | 1 | — | — | 1 | ||
| Intractable pain | D010148 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | 1 | 1 | — | — | 1 | 2 | ||
| Urinary bladder neoplasms | D001749 | C67 | 1 | 1 | — | — | 1 | 2 | |
| Inflammation | D007249 | — | 1 | — | — | — | 1 | ||
| Peripheral nervous system diseases | D010523 | G64 | — | 1 | — | — | — | 1 | |
| Critical illness | D016638 | 1 | 1 | — | — | — | 1 | ||
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | 1 | — | — | — | 1 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | 1 | — | — | — | 1 |
| Aids-associated nephropathy | D016263 | EFO_0007313 | — | 1 | — | — | — | 1 | |
| Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | 1 | — | — | — | 1 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | — | — | — | 1 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 6 | — | — | — | 1 | 7 | ||
| Infections | D007239 | EFO_0000544 | 2 | — | — | — | — | 2 | |
| Hepacivirus | D016174 | 1 | — | — | — | — | 1 | ||
| Kyphosis | D007738 | HP_0002808 | M40.20 | 1 | — | — | — | — | 1 |
| Intervertebral disc degeneration | D055959 | HP_0008419 | 1 | — | — | — | — | 1 | |
| Spondylolisthesis | D013168 | EFO_0007493 | M43.1 | 1 | — | — | — | — | 1 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | 1 | — | — | — | — | 1 | ||
| Candidiasis | D002177 | B37 | 1 | — | — | — | — | 1 | |
| Vomiting | D014839 | HP_0002013 | R11.1 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | — | 1 | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | — | 1 | 1 | ||
| Leukemia | D007938 | C95 | — | — | — | — | 1 | 1 | |
| Myelodysplastic syndromes | D009190 | D46 | — | — | — | — | 1 | 1 | |
| Myeloproliferative disorders | D009196 | D47.1 | — | — | — | — | 1 | 1 | |
| Lymphoma | D008223 | C85.9 | — | — | — | — | 1 | 1 | |
| Precancerous conditions | D011230 | — | — | — | — | 1 | 1 | ||
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | — | — | — | 1 | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | METHAMPHETAMINE |
| INN | metamfetamine |
| Description | Methamphetamine[note 1] (contracted from N-methylamphetamine) is a potent central nervous system (CNS) stimulant that is mainly used as a recreational drug and less commonly as a second-line treatment for attention deficit hyperactivity disorder and obesity. Methamphetamine was discovered in 1893 and exists as two enantiomers: levo-methamphetamine and dextro-methamphetamine.[note 2] Methamphetamine properly refers to a specific chemical substance, the racemic free base, which is an equal mixture of levomethamphetamine and dextromethamphetamine in their pure amine forms, but the hydrochloride salt, commonly called crystal meth, is widely used. Methamphetamine is rarely prescribed over concerns involving human neurotoxicity and potential for recreational use as an aphrodisiac and euphoriant, among other concerns, as well as the availability of safer substitute drugs with comparable treatment efficacy such as Adderall and Vyvanse. Dextroamphetamine is a stronger CNS stimulant than levomethamphetamine.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN[C@@H](C)Cc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 537-46-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201201 |
| ChEBI ID | 6809 |
| PubChem CID | 1206 |
| DrugBank | DB01577 |
| UNII ID | 44RAL3456C (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 35,905 documents
View more details
Safety
Black-box Warning
Black-box warning for: Desoxyn
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
28,472 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more